Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,106 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine.
Seeber A, Binder M, Steiner A, Wolff K, Pehamberger H. Seeber A, et al. Among authors: steiner a. Eur J Cancer. 1998 Dec;34(13):2129-31. doi: 10.1016/s0959-8049(98)00316-5. Eur J Cancer. 1998. PMID: 10070323
A complete response was noted in 3 patients (5%), a partial response in 4 patients (6%), stable disease in 33 patients (5%) and progressive disease in 23 patients (37%). ...Although there was a relatively low objective response rate, this chemotherapy regimen
A complete response was noted in 3 patients (5%), a partial response in 4 patients (6%), stable disease in 33 patients (5%) an
Epidermal growth factor facilitates melanoma lymph node metastasis by influencing tumor lymphangiogenesis.
Bracher A, Cardona AS, Tauber S, Fink AM, Steiner A, Pehamberger H, Niederleithner H, Petzelbauer P, Gröger M, Loewe R. Bracher A, et al. Among authors: steiner a. J Invest Dermatol. 2013 Jan;133(1):230-8. doi: 10.1038/jid.2012.272. Epub 2012 Sep 6. J Invest Dermatol. 2013. PMID: 22951723
As lymph node metastasis usually represents the first major step in melanoma progression, we were trying to identify a potential role of primary tumor-derived EGF in the mediation of melanoma lymph node metastases. ...Only in EGF-high melanoma cells, EGFkd led to a
As lymph node metastasis usually represents the first major step in melanoma progression, we were trying to identify a potential role …
Serum levels of glycoprotein Dickkopf-1 in patients with cutaneous malignant melanoma: a prospective pilot study.
Feldmann R, Schierl M, Fink AM, Sator PG, Maiweg J, Steiner A. Feldmann R, et al. Among authors: steiner a. Dermatology. 2011;222(2):171-5. doi: 10.1159/000324516. Epub 2011 Mar 8. Dermatology. 2011. PMID: 21389688 Clinical Trial.
Our in vivo data indicate that a decrease in Dkk-1 could be a sign of loss of tumor control....
Our in vivo data indicate that a decrease in Dkk-1 could be a sign of loss of tumor control....
Value of micromorphometric criteria of sentinel lymph node metastases in predicting further nonsentinel lymph node metastases in patients with melanoma.
Fink AM, Weihsengruber F, Duschek N, Schierl M, Wondratsch H, Jurecka W, Rappersberger K, Steiner A. Fink AM, et al. Among authors: steiner a. Melanoma Res. 2011 Apr;21(2):139-43. doi: 10.1097/CMR.0b013e328343ecf4. Melanoma Res. 2011. PMID: 21317817 Clinical Trial.
Especially, in patients with SN metastases in subcapsular location, a maximum depth of invasion of less than 0.3 mm (stage I according to the S-classification) or metastases of less than 0.1 mm in diameter had a very low probability of further non-SN metastases (0-5 …
Especially, in patients with SN metastases in subcapsular location, a maximum depth of invasion of less than 0.3 mm (stage I accordin …
Validation of the S classification of sentinel lymph node and microanatomic location of sentinel lymph node metastases to predict additional lymph node involvement and overall survival in breast cancer patients.
Fink AM, Wondratsch H, Lass H, Janauer M, Sevelda P, Salzer H, Jurecka W, Ulrich W, Chott A, Steiner A. Fink AM, et al. Among authors: steiner a. Ann Surg Oncol. 2011 Jun;18(6):1691-7. doi: 10.1245/s10434-010-1545-7. Epub 2011 Jan 20. Ann Surg Oncol. 2011. PMID: 21249455
Especially patients with a maximum depth of invasion ≤0.3 mm (stage I according to the S classification) and those with SN metastases only in subcapsular location had a low probability of further non-SN metastases (7.8 and 6.1%) and a good prognosis for OS. . …
Especially patients with a maximum depth of invasion ≤0.3 mm (stage I according to the S classification) and those with SN metastases …
S-classification of sentinel lymph node predicts axillary nonsentinel lymph node status in patients with breast cancer.
Fink AM, Lass H, Hartleb H, Jurecka W, Salzer H, Steiner A. Fink AM, et al. Among authors: steiner a. Ann Surg Oncol. 2008 Mar;15(3):848-53. doi: 10.1245/s10434-007-9694-z. Epub 2007 Nov 28. Ann Surg Oncol. 2008. PMID: 18043975
METHODS: Specimens of positive SN were subjected to a pathological review according to the previously published S-classification. ...RESULTS: Of 117 patients who underwent sentinel lymph node biopsy, 36 (30.8%) had a positive SN and were subjected to level I and II …
METHODS: Specimens of positive SN were subjected to a pathological review according to the previously published S-classification. ... …
Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E, Soyer HP, Posch M, Mossbacher U, Bauer P, Teban L, Svolba G, Wolf IH, Fritsch P, Zelger B, Volc-Platzer B, Gebhart W, Mischer P, Steiner A, Pachinger W, Hintner H, Gschnait F, Rappersberger K, Pilarski P, Pehamberger H; European Cooperative Adjuvant Melanoma Treatment Study Group. Richtig E, et al. Among authors: steiner a. J Clin Oncol. 2005 Dec 1;23(34):8655-63. doi: 10.1200/JCO.2004.00.8128. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260701 Clinical Trial.
PURPOSE: The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma cell lines, but it remained unclear whether this combination is more effective than IFNalpha alone in patients with metastatic melanoma. .. …
PURPOSE: The combination of interferon alfa (IFNalpha) and isotretinoin has shown a direct antiproliferative effect on human melanoma …
Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II.
Fink AM, Holle-Robatsch S, Herzog N, Mirzaei S, Rappersberger K, Lilgenau N, Jurecka W, Steiner A. Fink AM, et al. Among authors: steiner a. Melanoma Res. 2004 Apr;14(2):141-5. doi: 10.1097/00008390-200404000-00011. Melanoma Res. 2004. PMID: 15057045
Of the 48 patients included in the study, eight (16.7%) had a positive SNB. PET was positive in only one patient with a positive SNB, yielding a sensitivity of 13%. ...
Of the 48 patients included in the study, eight (16.7%) had a positive SNB. PET was positive in only one patient with a positi …
S-classification of sentinel lymph node biopsy predicts the results of complete regional lymph node dissection.
Fink AM, Weihsengruber F, Spangl B, Feichtinger H, Lilgenau N, Rappersberger K, Jurecka W, Steiner A. Fink AM, et al. Among authors: steiner a. Melanoma Res. 2005 Aug;15(4):267-71. doi: 10.1097/00008390-200508000-00006. Melanoma Res. 2005. PMID: 16034304
A series of consecutive patients with primary malignant melanoma stage I and II were evaluated retrospectively. The results of SLN biopsy in 26 patients with positive SLNs were compared with those of complete regional lymph node dissection (RLND) using the recently publish
A series of consecutive patients with primary malignant melanoma stage I and II were evaluated retrospectively. The results of SLN bi
Malignant peripheral nerve sheath tumor in three patients of advanced age.
Wruhs M, Feldmann R, Breier F, Steiner A. Wruhs M, et al. Among authors: steiner a. J Dtsch Dermatol Ges. 2016 Jan;14(1):72-4. doi: 10.1111/ddg.12508. J Dtsch Dermatol Ges. 2016. PMID: 26713647 English, German. No abstract available.
1,106 results
Jump to page
Feedback